English
A comprehensive review on drug-induced diseases and teratogenicity
Prathamesh V Chaudhari
Reshma Jadhav
Ashish Jain
Priya D Jagtap
Bhavesh D Mahajan
Prapti Gawand
Abstract
The phrase "drug induced disease" refers to an unintentional pharmacological side effect that causes mortality and morbidity and symptoms severe enough to necessitate hospitalization or medical attention. Anticoagulants, anticonvulsant, anti-seizure agents, antiepileptics, and antihistamines are among the drugs whose fetal developmental toxicity has been shown by epidemiological studies. These drugs can cause miscarriage, birth defects, and other adverse pregnancy outcomes. The primary method for diagnosing drug-related disorders in patients is the patient's or their family's history of drug use. The term "teratogenicity" describes the incidence of congenital defects brought on by teratogenic substances. Various pharmacogenetics has been studied in relation with the teratogenic mechanisms including folate antagonism, oxidative stress, inhibition of the angiotensin-converting enzyme (ACE) and angiotensin II receptor. Physical factors like ionizing radiation and toxic metals, chemical exposures, and pharmaceutical treatments including thalidomide, excessive vitamin A, corticosteroids, antiepileptic, anti-seizure, and antihypertensive medications are some of the sources of teratogenic abnormalities. To receive treatment for drug-induced problems, a patient must first notify a physician. During the course of the two-year trial period, 2381 ADR (Adverse drug reaction) events were reported in total, and 926 (38.89%) of them were drug-induced diseases.
Keywords:
Drug-induced diseases, iatrogenic diseases, adverse drug reactions, teratogenicity, teratogenic agentsSimilar Articles
- Agnieszka Lembas, Andrzej Załęski, Tomasz Mikuła, Joanna Jabłońska, Szymon Barczak, Barbara Badura, Alicja Wiercińska-Drapało, Differences in the course of hepatocellular carcinoma depending on the DAA treatment , Prospects in Pharmaceutical Sciences: Vol. 22 No. 3 (2024)
- Mateusz Sobczyk, Daria Żuraw, Paulina Oleksa, Kacper Jasiński, Mikołaj Porzak, Michał Dacka, SGLT2 inhibitors and their possible use in prevention and treatment of neurological diseases , Prospects in Pharmaceutical Sciences: Vol. 22 No. 1 (2024)
- Łukasz Dobrek, Analysis of the activity of the Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in the field of clinical trials, registration of medicinal products and monitoring of adverse drug reactions in 2017-2021 , Prospects in Pharmaceutical Sciences: Vol. 20 No. 4 (2022)
- Aleksandra Mikulska, Arkadiusz Kocur, Pharmacotherapy with high doses of methotrexate (HDMTX) in oncology – how should chemotherapy be conducted based on therapeutic drug monitoring? , Prospects in Pharmaceutical Sciences: Vol. 21 No. 4 (2023)
- Anna Dominiczak, Agata Janczak, Martyna Wołek, Katarzyna Mazurek, Maciej Bara, Proton pump inhibitors: prolonged intake and adverse effects , Prospects in Pharmaceutical Sciences: Vol. 22 No. 4 (2024)
- Bartłomiej Kot, Mateusz Moczulski, Agnieszka Czajkowska, Arkadiusz Kocur, Pharmacotherapy of apnea in the premature neonatological subpopulation – therapeutic opportunities, pharmacokinetic implications and recommendations for therapeutic drug monitoring , Prospects in Pharmaceutical Sciences: Vol. 22 No. 2 (2024)
- Szymon Barczak, Barbara Badura, Agnieszka Lembas, Tomasz Mikuła, Alicja Wiercińska-Drapało, Severe course of HIV-related Kaposi’s sarcoma with cutaneous, visceral and oral manifestations in a late-presenting patient , Prospects in Pharmaceutical Sciences: Vol. 22 No. 2 (2024)
- Paulina Oleksa, Daria Żuraw, Kacper Jasiński, Mateusz Sobczyk, Mikołaj Porzak, Alicja Sodolska, Karolina Haczkur-Pawłowska, Drugs and other chemical substances inducing diabetes – review of the literature , Prospects in Pharmaceutical Sciences: Vol. 22 No. 2 (2024)
- Kinga Sosnowicz, Monika Czerwińska, Plant materials used in eye diseases - from use in traditional medicine to research in antioxidant, anti - inflammatory, and antibacterial activity , Prospects in Pharmaceutical Sciences: Vol. 22 No. 3 (2024)
- Jakub Olszewski, Katarzyna Kozon, Magdalena Sitnik, Katarzyna Herjan, Karolina Mikołap, Bartłomiej Gastoł, Maciej Bara, Piotr Armański, Marcin Sawczuk, Mirikizumab – a new option in the treatment of inflammatory bowel diseases , Prospects in Pharmaceutical Sciences: Vol. 22 No. 3 (2024)
You may also start an advanced similarity search for this article.
Details
References
Statistics
Authors
Citation rules
Cited by / Share
Licence
This work is licensed under a Creative Commons Attribution 4.0 International License.